Literature DB >> 2408800

Interferon deficiency syndrome.

S Levin, T Hahn.   

Abstract

Activation of the interferon (IFN) system is an early defence mechanism against viral infections. The virus stimulates production of IFN by nucleated cells including the peripheral blood mononuclear cells (PBMC), and this IFN in turn activates several IFN-dependent immune mechanisms including the induction of an anti-viral state in cells, which prevents or retards further intracellular viral replication. In an ongoing study of 1,500 individuals of all ages and with various illnesses, we found 15 cases (representing 5% of patients with acute viral disease) in whom the IFN system response during an acute viral illness was absent or grossly deficient. There was no detectable IFN in the blood, PBMC did not produce IFN-alpha and IFN-gamma or produced minimal amounts of one of them in vitro following appropriate stimulation, and the patients' PBMC were not in an anti-viral state. These patients had severe progressive or fulminant viral disease, often ending fatally. IFN therapy appears to be beneficial in these cases, as it rapidly induced a cellular antiviral state in most cases, stimulated in vitro IFN-alpha and IFN-gamma production by PBMC, and led to rapid recovery in seven of the nine patients who received treatment for at least 3 days. In our opinion IFN replacement therapy should be commenced as early as possible in such cases, and before irreversible cell and organ damage occur.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2408800      PMCID: PMC1577037     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  Interferon response of lymphocytes in disorders with decreased resistance to infections.

Authors:  H Strander; K Cantell; J Leisti; E Nikkila
Journal:  Clin Exp Immunol       Date:  1970-02       Impact factor: 4.330

3.  Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia.

Authors:  J Pedersen-Bjergaard; S Haahr; P Philip; M Thomsen; G Jensen; J Ersbøll; N I Nissen
Journal:  Br J Haematol       Date:  1980-10       Impact factor: 6.998

4.  Evaluation of T lymphocyte effector function in immunodeficiency diseases: abnormality in mitogen-stimulated interferon in patients with selective IgA deficiency.

Authors:  L B Epstein; A J Ammann
Journal:  J Immunol       Date:  1974-02       Impact factor: 5.422

5.  Absent serum interferon in chronic lymphatic leukemia.

Authors:  H Ludwig
Journal:  N Engl J Med       Date:  1979-11-01       Impact factor: 91.245

6.  Thymic dysplasia ("Swiss agammaglobulinemia"). II. Morphologic and functional observations.

Authors:  M E Miller; K Hummeler
Journal:  J Pediatr       Date:  1967-05       Impact factor: 4.406

7.  Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis.

Authors:  P A Neighbour; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

8.  Thymic deficiency in Down's syndrome.

Authors:  S Levin; M Schlesinger; Z Handzel; T Hahn; Y Altman; B Czernobilsky; J Boss
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

9.  Production of immune and viral interferon by lymphocytes of newborn infants.

Authors:  T Hahn; S Levin; Z T Handzel
Journal:  Isr J Med Sci       Date:  1980-01

10.  Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion.

Authors:  J L Virelizier; G Lenoir; C Griscelli
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

View more
  9 in total

Review 1.  Hepatic disorders. Features and appropriate management.

Authors:  M A Aldersley; J G O'Grady
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

2.  Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.

Authors:  J Portnoy; R Hicks; F Pacheco; L Olson
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

Review 3.  Transgenic models for cytokine-induced neurological disease.

Authors:  Iain L Campbell; Markus J Hofer; Axel Pagenstecher
Journal:  Biochim Biophys Acta       Date:  2009-10-14

Review 4.  Intensive liver care and management of acute hepatic failure.

Authors:  R Williams; A E Gimson
Journal:  Dig Dis Sci       Date:  1991-06       Impact factor: 3.199

Review 5.  A review of the efficacy of adenine arabinoside and lymphoblastoid interferon in the Royal Free Hospital studies of hepatitis B virus carrier treatment: identification of factors influencing response rates.

Authors:  H C Thomas; L J Scully; A M Lever; I Yap; M Pignatelli
Journal:  Infection       Date:  1987       Impact factor: 3.553

6.  Deciphering the modulation of gene expression by type I and II interferons combining 4sU-tagging, translational arrest and in silico promoter analysis.

Authors:  Mirko Trilling; Nicolás Bellora; Andrzej J Rutkowski; Miranda de Graaf; Paul Dickinson; Kevin Robertson; Olivia Prazeres da Costa; Peter Ghazal; Caroline C Friedel; M Mar Albà; Lars Dölken
Journal:  Nucleic Acids Res       Date:  2013-07-05       Impact factor: 16.971

7.  A Dual-Functioning 5'-PPP-NS1shRNA that Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1.

Authors:  Neetu Singh; Priya Ranjan; Weiping Cao; Jenish Patel; Shivaprakash Gangappa; Bruce A Davidson; John M Sullivan; Paras N Prasad; Paul R Knight; Suryaprakash Sambhara
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-31       Impact factor: 8.886

8.  Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus.

Authors:  Anderson Dik Wai Luk; Ke Ni; Yuet Wu; Kwok-Tai Lam; Koon-Wing Chan; Pamela P Lee; Wenwei Tu; Huawei Mao; Yu Lung Lau
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

Review 9.  A systematic approach to virus-virus interactions.

Authors:  T DaPalma; B P Doonan; N M Trager; L M Kasman
Journal:  Virus Res       Date:  2010-01-20       Impact factor: 3.303

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.